Highest-materiality recent filing
Edgewise sells sevasemten to Servier for $1.55B upfront, plus up to $1.1B milestones
$1.55B upfront cash; potential $1.1B in regulatory and commercial milestones totaling up to $2.65B.
Edgewise Q1 net loss $49M, cash $499.6M; sevasemten Becker data up to 3.5 years
Net loss $49.0M ($0.46/share) in Q1 2026 vs $40.8M ($0.43/share) in Q1 2025; cash and equivalents $499.6M.
Edgewise reports Q4 net loss $50.2M ($0.47/sh); cash $530M; key trial readouts in 2026
Net loss for Q4 2025 was $50.2M ($0.47/sh) vs $40.7M ($0.39/sh) in prior quarter; no revenue.
Edgewise Therapeutics appoints Christopher Martin to Board of Directors
Martin, former CCO of Verona Pharma (acquired by Merck for ~$10B), joins as Class I director.
Edgewise Therapeutics appoints Michael Nofi as CFO, succeeding retiring CFO Carruthers
Michael Nofi appointed CFO effective Nov 10, 2025; replaces R. Michael Carruthers who retired.
Edgewise Q3 net loss $40.7M ($0.39/sh); cash $563.3M; GRAND CANYON data Q4 2026
Cash, equivalents and marketable securities $563.3M at Sep 30, 2025.
Edgewise Q2 net loss $36.1M; positive sevasemten data in Becker, Duchenne
Net loss of $36.1M ($0.34/share) for Q2 2025; cash and equivalents $594M as of June 30.
Edgewise announces positive sevasemten data; FDA provides clear path to first Becker therapy
MESA OLE: 99% enrollment (85 participants); NSAA scores improved 0.8 pts over 18 months, diverging from natural history declines.
Edgewise Q1 net loss $40.8M; positive Phase 2 HCM data and $188M offering highlighted
Positive top-line data from Phase 2 CIRRUS-HCM: EDG-7500 reduced LVOT-G without meaningful LVEF changes; improved KCCQ and NT-proBNP.
Edgewise reports positive Phase 2 data for EDG-7500 in HCM; 71% LVOT-G reduction at rest
Obstructive HCM: 100 mg dose achieved mean 71% reduction in resting LVOT-G and 58% in provokable gradients over 4 weeks.
Edgewise Therapeutics prices $200M common stock offering at $20.13 per share
9,935,419 shares priced at $20.13; gross proceeds ~$200M before discounts and expenses.
Edgewise Therapeutics reports Q4 2024 net loss of $39.7M; pipeline milestones on track
Net loss $39.7M ($0.42 per share) for Q4 2024; cash and equivalents $470.2M as of Dec 31, 2024.
Edgewise Therapeutics promotes Behrad Derakhshan to COO
Behrad Derakhshan, Ph.D., appointed Chief Operating Officer effective January 8, 2025.
Primary endpoint met: CK decreased 28% vs placebo over months 6-12 in adults (p=0.02).
Edgewise Q3 net loss $34.1M; Phase 2 CANYON data on track for Dec 2024
Net loss $34.1M ($0.36 per share) vs $31.5M ($0.34) prior quarter; cash $492.5M.
Edgewise Therapeutics adopts 2024 Inducement Plan, reserving 2M shares for new hires
Board adopted 2024 Inducement Equity Incentive Plan effective August 10, 2024, reserving 2,000,000 shares of common stock.
Edgewise Therapeutics Q2 2024 net loss $31.5M; cash $511.8M; EDG-7500 Phase 1 complete
Net loss of $31.5M ($0.34 per share) vs $28.5M in prior quarter; no product revenue.
Edgewise shareholders elect directors, ratify KPMG, approve officer exculpation charter amendment
Elected Class III directors Thompson, Koch, and Fox with 65M–75M shares For vs 6.9M–17.3M Against; broker non-votes 8.2M.
Edgewise Therapeutics enters $175M ATM equity offering with Leerink Partners
New Sales Agreement with Leerink Partners for at-the-market offering of up to $175M common stock.
Edgewise Q1 net loss $28.5M; sevasemten shows positive Becker data
Cash, cash equivalents and marketable securities $532.8M as of March 31, 2024.
Edgewise Therapeutics appoints Arlene Morris to Board of Directors, effective May 6, 2024
Morris replaces Peter Thompson on the Audit and Compensation Committees.
On January 8, 2025, the Board of Directors (the “ Board ”) of Edgewise Therapeutics, Inc. (the “ Company ”) promoted Behrad Derakhshan, Ph.D. to the role of Chief Operating Officer of the Company, effective immediately.
On May 6, 2024, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Arlene Morris to serve (i) as a Class I director, with a term expiring at the Company’s 2025 annual meeting of stockholders, (ii) as a member of the Audit Committee of the Board (the “Audit Committee”), and (iii) as a member of the Compensation Committee of the Board (the “Compensation Committee”), replacing Peter Thompson as a member of the Audit Committee and Compensation Committee.
Max materiality 1.00 · Median 0.65 · Most common event earnings